Rupture of non-occlusive cerebrovascular lesions, such as intracranial saccular aneurysms, arterio-venous malformations, and arterio-venous fistulae, is a major cause of stroke. Rupture of a lesion causes subarachnoid hemorrhage in which blood from a ruptured vessel spreads over the surface of the brain. About 2.5% of the United States population (4 million Americans) have an unruptured lesion. About 100,000 of these people suffer a subarachnoid hemorrhage each year. The disease is devastating, often affecting healthy people in their 40's and 50's, with half of the rupture victims succumbing within a month, and with half the survivors becoming seriously disabled as a result of the initial hemorrhage or of a delayed complication.
Neurovascular arteries are generally quite small, having a diameter ranging from 2.0 to 4.0 mm in the Circle of Willis, 2.5 to 5.5 mm in the cavernous segment of the internal carotid artery, 1.5 to 3.0 mm in the vessels of the distal anterior circulation, and 2.0 to 4.0 mm in the posterior circulation. The incidence of non-occlusive cerebrovascular lesions varies with the location, with 50% occurring in the Circle of Willis, 30% in the internal carotid, 15% in the distal anterior circulation, and 5% in the posterior circulation.
Screening for these lesions and preventing rupture will lead to better clinical outcomes and lower costs. Non-invasive treatments for ruptured and unruptured lesions are preferred over surgical interventions due to lower costs, lower mortality and morbidity, and patient preference.
An increasing number of non-invasive treatments are multi-modal, i.e. they utilize two or more different treatments to cure a single lesion. For example, many aneurysms are treated by implanting a stent across the neck of the aneurysm, then filling the aneurysm sac with detachable metallic coils (such as Guglielmi Detachable Coils (Boston Scientific/Target of Fremont, Calif.)) or with a liquid embolic (such as Onyx (Micro Therapeutics, Inc. of San Clemente, Calif.)). Arterio-venous malformations may be treated using a combination of pushable coils, such as those available from Cook Corporation of Bloomington, Indiana, and glue, such as NBCA available from Cordis Neuro Vascular of Miami Lakes, Fla.
However, prior art delivery systems are suitable for only a single treatment modality. As a result, multi-modal treatments require the physicians to utilize several delivery systems. Each time a new delivery system is required, the physician must remove the old delivery system, insert the new delivery system, and re-access the lesion. These extra steps increase the time and the risk of the procedure. It is also possible that it will be impossible to re-access the lesion, resulting in a treatment failure.
It would therefore be valuable to provide a delivery system that permits multi-modal treatment to be performed using a single delivery device.
The invention, in one aspect, includes three elements:
In one embodiment, the outer catheter is a 3 French O.D. microcatheter, which may be a variable-stiffness microcatheter; may be braided; may have a lubricious inner liner; and may be coated on the O.D. with a hydrophilic or other lubricious coating. The outer catheter is capable of accessing lesions through tortuous anatomy, such as lesions deep in the intracranial circulation. The outer catheter may have an I.D. of approximately 2.1 French.
In this embodiment, the inner catheter has an O.D. of 2 French, allowing it to fit inside the outer catheter. The inner catheter has an I.D. of approximately 0.016″. The inner catheter may have two platinum tip markers, spaced to permit deployment of electrolytically detachable coils (such as Guglielmi Detachable Coils). The inner catheter may be composed of materials that are compatible with liquid embolics, including DMSO-based embolics (such as Onyx).
In this embodiment, the guidewire has an O.D. of approximately 0.014″.
In another embodiment, a self-expanding stent is loaded into the distal end of the outer catheter. The stent can be compressed and placed into the I.D. of the catheter, such that stent can be advanced proximally and distally through the I.D. of the catheter. The inner catheter is designed such that the distal tip of the inner catheter butts against the proximal end of the stent. The inner catheter is capable of pushing the stent distally, out of the outer catheter, in order to deploy the stent.
In yet another embodiment, the outer catheter is designed to permit pushable coils to be introduced into the catheter hub and be pushed through the catheter I.D. (such as 0.025″ pushable coils).
The inner catheter is designed such that the distal tip of the inner catheter butts against the pushable coil. The inner catheter is capable of pushing the pushable coil distally, through the outer catheter, in order to deliver the coil.
In addition, the inner catheter also permits pushable coils (such as 0.010″ pushable coils) to be introduced into the catheter hub and pushed through the catheter I.D. A standard coil pusher (such as an 0.014″ coil pusher) is capable of pushing the pushable coil distally, through the inner catheter, in order to deliver the coil.
This application claims priority to U.S. Provisional Application Ser. No. 60/279,172 filed Mar. 27, 2001, which is incorporated in its entirety herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3868956 | Alfidi et al. | Mar 1975 | A |
4494531 | Gianturco | Jan 1985 | A |
4503569 | Dotter | Mar 1985 | A |
4512338 | Balko et al. | Apr 1985 | A |
4820298 | Leveen et al. | Apr 1989 | A |
4923464 | DiPisa, Jr. | May 1990 | A |
4994069 | Ritchart et al. | Feb 1991 | A |
5108407 | Geremia et al. | Apr 1992 | A |
5122136 | Guglielmi et al. | Jun 1992 | A |
5203777 | Lee | Apr 1993 | A |
5217484 | Marks | Jun 1993 | A |
5234437 | Sepetka | Aug 1993 | A |
5250071 | Palermo | Oct 1993 | A |
5261916 | Engelson | Nov 1993 | A |
5304195 | Twyford et al. | Apr 1994 | A |
5350397 | Palermo et al. | Sep 1994 | A |
5354295 | Guglielmi et al. | Oct 1994 | A |
5423829 | Pham et al. | Jun 1995 | A |
5624449 | Pham et al. | Apr 1997 | A |
5667767 | Greff et al. | Sep 1997 | A |
5669905 | Scheldrup et al. | Sep 1997 | A |
5690671 | McGurk et al. | Nov 1997 | A |
5695480 | Evans et al. | Dec 1997 | A |
5702361 | Evans et al. | Dec 1997 | A |
5830178 | Jones et al. | Nov 1998 | A |
5851508 | Greff et al. | Dec 1998 | A |
5855578 | Guglielmi et al. | Jan 1999 | A |
5879361 | Nash | Mar 1999 | A |
5891128 | Gia et al. | Apr 1999 | A |
5891130 | Palermo et al. | Apr 1999 | A |
5895385 | Guglielmi et al. | Apr 1999 | A |
5925037 | Guglielmi et al. | Jul 1999 | A |
5925062 | Purdy | Jul 1999 | A |
5928226 | Guglielmi et al. | Jul 1999 | A |
5935148 | Villar et al. | Aug 1999 | A |
5941888 | Wallace et al. | Aug 1999 | A |
5944714 | Guglielmi et al. | Aug 1999 | A |
5947962 | Guglielmi et al. | Sep 1999 | A |
5947963 | Guglielmi | Sep 1999 | A |
5964797 | Ho | Oct 1999 | A |
5976126 | Guglielmi | Nov 1999 | A |
5984929 | Bashiri et al. | Nov 1999 | A |
6010498 | Guglielmi | Jan 2000 | A |
6017977 | Evans et al. | Jan 2000 | A |
6063070 | Eder | May 2000 | A |
6063104 | Villar et al. | May 2000 | A |
6066133 | Guglielmi et al. | May 2000 | A |
6077260 | Wheelock et al. | Jun 2000 | A |
6083220 | Guglielmi et al. | Jul 2000 | A |
6086577 | Ken et al. | Jul 2000 | A |
6146373 | Cragg et al. | Nov 2000 | A |
6156061 | Wallace et al. | Dec 2000 | A |
6165178 | Bashiri et al. | Dec 2000 | A |
6193708 | Ken et al. | Feb 2001 | B1 |
6281263 | Evans et al. | Aug 2001 | B1 |
6303100 | Ricci et al. | Oct 2001 | B1 |
6335384 | Evans et al. | Jan 2002 | B1 |
6342202 | Evans et al. | Jan 2002 | B1 |
6344041 | Kupiecki et al. | Feb 2002 | B1 |
Number | Date | Country | |
---|---|---|---|
20020161342 A1 | Oct 2002 | US |
Number | Date | Country | |
---|---|---|---|
60279172 | Mar 2001 | US |